Investor Presentation

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com BIO/SECL/TG/2026-27/81 November 04, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services, Corporate Communication Department, Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Dear Sir/Madam, Subject: Presentation – Q2 FY27 Earnings Call Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation w.r.t. Q2 FY27 Earnings Call to be conducted on November 04, 2026. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the above information on record. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328 Enclosed: as above Biocon Limited Q2 FY27 Earnings Call 04 – Nov – 2026 Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. Chairperson’s Opening Remarks Biocon at an Inflection Point: From Investment to Value Creation ▪ Well positioned for structural industry shifts, supported by Biocon’s global Biosimilars platform and Syngene’s integrated research, development and manufacturing capabilities ▪ Transitioning from investment-led capability building to commercial acceleration, with increasing focus on operating leverage, cash generation and shareholder value ▪ H1 FY27 execution milestones strengthen the foundation for a stronger H2, including additional insulin capacity and continued regulatory and commercial progress ▪ Pertuzumab demonstrates our ability to navigate both regulatory and IP pathways, with the positive CHMP opinion and Genentech settlement providing greater visibility on commercialization across key markets Expanding Market Presence across Key Geographies ▪ North America ❖ Established products continued to demonstrate resilience, with Ogivri® and Fulphila® maintaining leadership positions ❖ Yesintek® sustained its positive momentum, supported by market-share gains and improving access ❖ Yesafili recorded an encouraging US launch, supported by new contracts and important payor wins ▪ Europe ❖ Portfolio expansion continued with launches of ustekinumab, denosumab and aflibercept across several markets ❖ Approximately 20 tender awards across Italy, Spain, France and Denmark strengthen broader market access ❖ Positive CHMP opinion for Pertuzumab and regulatory progress for insulin glargine support the future growth pipeline ▪ Emerging Markets ❖ Thirteen new launches across APAC, Latin America and AFMET-CIS broadened the commercial footprint ❖ The 10-year Pertuzumab partnership in Brazil provides long-term revenue visibility in an important biologics market ❖ The partnership with Biomm supports the semaglutide strategy in Brazil, extending the GLP-1 opportunity into EMs MD & CEO Remarks Financial Highlights: Q2 FY27 In ₹ Cr Q2 FY27 Q2 FY26 Q1 FY27 YoY% QoQ% Biopharmaceuticals 3,583 3,422 3,614 5 (1) - Biosimilars 2,809 2,721 2,855 3 (2) - Generics 774 701* 760 10 2 Services 833 911 736 (9) 13 Revenue from Operations 4,389 4,296 4,336 2 1 Total Revenue 4,423 4,389 4,391 1 1 R&D (Net) 237 251 240 (6) (1) % of Revenue (Ex. Syngene) 7 7 7 EBITDA 865 928 902 (7) (4) % Margin 20 22 21 Profit Before Tax 62 183 141 (66) (56) (Before exceptional items) % Margin 1 4 3 Net Profit 44 92 145 (52) (70) (Before exceptional items) Exceptional item, net of tax & NCI (3) (7) (4) Net Profit (Reported) 41 85 141 (52) (71) * Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under “Unallocable expenditure/(income)” Financial Highlights: H1 FY27 In ₹ Cr H1 FY27 H1 FY26 YoY% Biopharmaceuticals 7,200 6,511 11 - Biosimilars 5,664 5,179 9 - Generics 1,536 1,332 15 Services 1,569 1,785 (12) Revenue from Operations 8,725 8,237 6 Total Revenue 8,814 8,410 5 R&D (Net) 477 455 5 % of Revenue (Ex. Syngene) 7 7 EBITDA 1,767 1,774 0 % Margin 20 22 Profit Before Tax 203 297 (32) (Before exceptional items) % Margin 2 4 Net Profit 189 133 42 (Before exceptional items) Exceptional item, net of tax & NCI (7) (17) Net Profit (Reported) 182 116 57 * Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under “Unallocable expenditure/(income)” Biosimilars Biosimilars: Q2 FY27 Business Performance Update Q2 Q2 Q1 In ₹ Cr YoY% QoQ% ▪ Financial Performance FY27 FY26 FY27 ❖ Revenue stood at ₹2,809 Cr Segment 2,809 2,721 2,855 3 (2) Revenue ❖ EBITDA stood at ₹623 Cr; 22% margin R & D 202 180 192 12 5 ❖ Reported growth & margins impacted by timing of revenue % of Revenue 7.2% 6.6% 6.7% recognition on certain shipments EBITDA 623 669 728 (7) (14) % of Revenue 22% 25% 25% ▪ Yesafili delivered an encouraging US launch, while Yesintek® continued to perform well In ₹ Cr H1 FY27 H1 FY26 YoY% ▪ Insulin demand remained strong, supported by the Segment 5,664 5,179 9 additional fill-finish capacity commissioned in Malaysia Revenue R & D 394 314 25 ▪ 10-year Brazil Pertuzumab partnership, with US$400 % of Revenue 7.0% 6.1% million TCV, strengthens long-term revenue visibility EBITDA 1,351 1,331 2 % of Revenue 24% 26% ▪ H2 expected to be much stronger, supported by launch momentum and additional insulin capacity Generics Generics: Q2 FY27 Business Performance Update Q2 Q2 Q1 In ₹ Cr YoY% QoQ% ▪ Financial Performance FY27 FY26* FY27 ❖ Revenues grew 10% YoY Segment 774 701 760 10 2 Revenue ❖ EBITDA margin expanded by over 700bps YoY R & D 35 71 47 (51) (26) ❖ Improved capacity utilization, operating leverage and % of Revenue 5% 10% 6% productivity initiatives led to the improvement EBITDA 64 7 56 815 15 % of Revenue 8% 1% 7% ▪ Liraglutide gaining traction across markets, strengthening our complex injectables portfolio In ₹ Cr H1 FY27 H1 FY26* YoY% ▪ Peptides, fermentation & complex formulations Segment Revenue 1,536 1,332 15 underpin the next phase of growth R & D 82 141 (42) % of Revenue 5% 11% ▪ Continued execution and operating leverage to support EBITDA 120 (28) nm further improvement in profitability % of Revenue 8% (2)% * Excluding cross charge of common utilities that was earlier included within Generics but is now appropriately included under “Unallocable expenditure/(income)” Services Services: Q2 FY27 Business Performance Update ▪ Financial Performance In ₹ Cr Q2 FY27 [Showing first 8,000 characters — download PDF for full document]